Literature DB >> 8207340

Modulation of intraocular pressure by adenosine agonists.

C E Crosson1, T Gray.   

Abstract

Adenosine receptors have been shown to modulate a variety of physiological functions; however, little is known about the role these receptors play in the modulation of ocular function. To investigate the potential role of adenosine receptors in modulating intraocular pressure (IOP), the A1 agonist N6-cyclopentyladenosine (CPA), the nonselective adenosine agonist 5'-N-ethylcarboxamideadenosine (NECA) and the A2 agonist 8-phenylaminoadenosine (CV-1808) were evaluated. Topical administration of NECA produced a dose-related reduction in IOP. However, an initial ocular hypertension of 1 to 2 hours was also observed in rabbits treated with NECA. The administration of CPA (165 micrograms) resulted only in a reduction in IOP, while the administration of CV-1808 produced only an initial ocular hypertension. As adenosine A1 receptors have been shown to be negatively coupled to adenylate cyclase in several systems, CPA was evaluated for its ability to suppress cAMP formation in the isolated iris/ciliary body. CPA produced a dose-related suppression of cAMP accumulation induced by 10(-6) M forskolin (EC50 = 3.2 nM). These results indicate that selected adenosine agonists can modulate IOP. The ocular hypotension induced by adenosine agonists is consistent with the activation of adenosine A1 receptors and may involve the modulation of cAMP levels in the iris/ciliary body.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207340     DOI: 10.1089/jop.1994.10.379

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  5 in total

1.  Adenosine receptor distribution in Rhesus monkey ocular tissue.

Authors:  Krista M Beach; Li-Fang Hung; Baskar Arumugam; Earl L Smith; Lisa A Ostrin
Journal:  Exp Eye Res       Date:  2018-05-21       Impact factor: 3.467

2.  MRP4-mediated regulation of intracellular cAMP and cGMP levels in trabecular meshwork cells and homeostasis of intraocular pressure.

Authors:  Padmanabhan P Pattabiraman; Paula E Pecen; Ponugoti Vasantha Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-05       Impact factor: 4.799

Review 3.  Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.

Authors:  Vanessa Andrés-Guerrero; Julián García-Feijoo; Anastasios Georgios Konstas
Journal:  Adv Ther       Date:  2017-03-27       Impact factor: 3.845

4.  A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers.

Authors:  Alan Laties; Cadmus C Rich; Randall Stoltz; Vernon Humbert; Chaim Brickman; William McVicar; Rudolf A Baumgartner
Journal:  J Ocul Pharmacol Ther       Date:  2016-04-05       Impact factor: 2.671

5.  A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.

Authors:  Jonathan S Myers; Kenneth N Sall; Harvey DuBiner; Natanya Slomowitz; William McVicar; Cadmus C Rich; Rudolf A Baumgartner
Journal:  J Ocul Pharmacol Ther       Date:  2016-03-22       Impact factor: 2.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.